Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 206422, held by Lupin. Fluocinolone Acetonide.
As of Nov 16, 2026, ANDA 206422 (Fluocinolone Acetonide), held by Lupin, was first approved by FDA on Sep 2, 2015, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Fluocinolone Acetonide Topical Solution USP, 0.01% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 2, 2015 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fluocinolone Acetonide0.01% · solution;topical | Fluocinolone Acetonide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters